Last reviewed · How we verify
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
The purpose of this study is to characterize the effects of 85 days treatment with MLN1202 on urinary albumin-to-creatinine ratio (UACR) in participants with type 2 diabetes, advanced kidney disease/diabetic nephropathy (DN) and macro-albuminuria (UACR\>300 mg/g) based on average of 3 consecutive first morning voids sample collection.
Details
| Lead sponsor | Takeda |
|---|---|
| Phase | PHASE2 |
| Status | WITHDRAWN |
| Start date | Wed May 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Diabetic Nephropathy
Interventions
- MLN1202 Placebo
- MLN1202